PTGS2 and glioblastoma: In a recent study using glioma cell lines, Three COX-2 inhibitors NS-398, Celecoxib and Meloxicam, have been shown to reduce GBM proliferation and increase radiosensitization when used before initial radiotherapy, independent of differing COX-2 expression levels (113).